Angiotensin II receptor antagonist (Telmistartan 80mg/day) vs placebo

Polypharmacy icon of two pills

Study population:

Patients intolerant of ACE Inhibitors with:

established cardiovascular disease:

 

Coronary artery, peripheral vascular or cerebrovascular disease, or diabetes with end organ damage

Patients with heart failure were excluded.

Comments:

Mean age of patients was approx. 67 years.


Death rate (of any cause) was higher in treatment group than placebo group. When hospitalisations for cardiac failure were added to the composite endpoint as a primary outcome, the results were non-significant. Study concluded that telmisartan did not significantly reduce cardiovascular death.

 

Outcome Duration NNT Annualised NNT
Prevent one of a composite of cardiovascular death, MI or stroke. 56 months (median duration of followup)

55

258

References

Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I et al. Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. The Lancet. 2008; 372: 1174-1183